Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 or NY-ESO-1 Vaccine + Nivolumab in Recurrent Ovarian Cancer
NCT02737787Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2016
- Primary completion
- Apr 2023
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of galinpepimut-s and NY-ESO-1 OLP4 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose limiting toxicity at 30 days. Started Apr 2016; status: completed.
02
Drugs
galinpepimut-sNY-ESO-1 OLP4
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02737787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737787.